کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3064181 | 1580407 | 2014 | 6 صفحه PDF | دانلود رایگان |
• Successful scale up of antigen specific immunoadsorption method for MG therapy
• Several safety parameters of antigen specific immunoadsorption method were tested
• Neither pyrogen nor complement activation occur
• Whole blood apheresis as an alternative to plasma apheresis was successfully tested
• Antigen specific apheresis seems a safe and effective treatment for myasthenia gravis
Myasthenia gravis is an autoimmune disease usually caused by autoantibodies against the muscle nicotinic acetylcholine receptor (nAChR). Current treatments are not specific, and thus often cause side effects. Here, we elaborate on our previous findings on antigen specific immunoadsorption towards scaling up the method as well as testing whole blood apheresis. The average percent of plasma or whole blood immunoadsorption was up to 79.5% ± 2.9. Moreover, neither pyrogens were co-administered nor did complement activation occur after immunoadsorption. Thus, antigen-specific apheresis of anti-AChR autoantibodies seems a safe and effective treatment for myasthenia gravis that can be scaled up for clinical testing.
Journal: Journal of Neuroimmunology - Volume 267, Issues 1–2, 15 February 2014, Pages 1–6